Dr. Mouquet earned a BS in Biochemistry, a MS in Biochemistry & Molecular Biology and a PhD in Immunology from the University of Rouen (Normandy, France). He performed his post-doctoral trainee in the laboratory of Michel C. Nussenzweig at the Rockefeller University (2007-2013), where he studied B-cell antibody response to HIV-1, isolated and characterized HIV-1 bNAbs. In 2013, Hugo started his group as a young investigator in the immunology department of the Institut Pasteur, supported by an ERC starting grant award. He currently heads the laboratory of Humoral Immunology at the Institut Pasteur. His lab investigates the humoral responses to pathogens in humans with a focus on HIV-1, Hepatitis viruses and emerging infections, and a dual interest in basic and translational research.
CoVariant – Comprendre les déterminants de l’immunité muqueuse et optimiser le diagnostic de l’infection aux variants du SARS-CoV-2
Sorry, this entry is only available in French.
Antibody memory B-cell response to Chikungunya virus
Chikungunya is a mosquito-transmitted disease of sub-tropical areas caused by an alphavirus, the Chikungunya virus (CHIKV). CHIKV infection has re-emerged after several decades causing large outbreaks, making it an important public health concern. The […]
Humoral immunoprofiling in HIV-1 post-treatment controllers
Rare infected individuals who initiated antiretroviral therapy (ART) very early during primary infection can enter in remission after its interruption, a phenomenon known as post-treatment control. Interestingly, early treatment has been associated with the […]
Humoral immune response & immunotherapy in HBV infection
Human infections caused by hepatitis B virus (HBV) are major healthcare issues. Despite available effective vaccines, more than 250 million individuals worldwide are chronically infected by HBV, which accounts for approximately 1 million deaths […]
Humoral immunity & human monoclonal antibodies against SARS-CoV-2
The objective of this research project is to understand the molecular and functional basis of the memory B-cell antibody response to the SARS-CoV-2 Spike protein. One of the key goals of this research program […]
Archive of the Group for AIDS Research
This page contains the list of past meetings held by the Group for AIDS Research (Groupe de Réflexion SIDA) of the Pasteur Institute since 2014. The list of previous meetings held since 2002 can […]
Group for AIDS Research
The Group for AIDS Research (Groupe de Réflexion SIDA, GRS) organizes bimonthly meetings and seminars around an HIV / AIDS research topic. Since 2021, the meetings may also include topics related to emerging viruses. […]
Intestinal and IgA B-cell responses to HIV-1
Mucosal transmission of HIV-1 can induce a local production of IgG and IgA antibodies predominantly targeting the gp41 subunit of the viral envelope glycoprotein gp160. However, whether they limit viral dissemination upon HIV-1 exposure […]
Clonal B cells in HCV-induced cryoglobulinemia vasculitis
Hepatitis C virus (HCV) infection can trigger the development of autoimmune disorders among which, cryobulininemic vasculatitis is the most prevalent. HCV-associated cryobulininemic vasculatitis is mediated by mono-/oligo-clonal IgM cryoglobulins with rheumatoid factor activity, thought […]
Antiviral properties of broadly neutralizing HIV-1 antibodies
Broadly neutralizing HIV-1 antibodies (bNAbs) can develop in rare infected individuals several years after co-evolution with diversifying viruses. In animal models, passive immunotherapy with potent HIV-1 bNAbs has been shown to protect from infection […]
Human Antibody Responses to Viruses Adaptive immune responses naturally occurring upon infection or induced by vaccination generate high affinity antibodies, and memory B-cell subsets to respond to further antigenic challenges, providing protection against (re-)infections. […]
2023Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller., Cell Host Microbe 2023 Jul; (): .
2023Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies., Nat Commun 2023 Feb; 14(1): 824.
2023Tocilizumab treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants., iScience 2023 Feb; (): 106124.
2022Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters, Vaccines (Basel).
2022Full-Lung Prophylaxis against SARS-CoV-2 by One-Shot or Booster Intranasal Lentiviral Vaccination in Syrian Golden Hamsters., Vaccines (Basel) 2022 Dec; 11(1): .
2022Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies., Cell Rep Med 2022 Nov; (): 100850.
2022Evolutionary trajectory of receptor binding specificity and promiscuity of the spike protein of SARS-CoV-2., Protein Sci 2022 Nov; 31(11): e4447.
2022The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants., J Virol 2022 Oct; 96(19): e0130122.
2022IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies., Eur J Immunol 2022 Aug; (): .
2022NK cell spatial dynamics and IgA responses in gut-associated lymphoid tissues during SIV infections., Commun Biol 2022 Jul; 5(1): 674.
+View full list of publications